J Cancer 2019; 10(20):4739-4746. doi:10.7150/jca.35898

Research Paper

EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®

Konstantinos Sapalidis1, Paul Zarogoulidis1✉, Dimitris Petridis2, Christoforos Kosmidis1, Barbara Fyntanidou1, Kosmas Tsakiridis1, Elena Maragouli1, Aikaterini Amaniti3, Dimitris Giannakidis1, Charilaos Koulouris1, Stylianos Mantalobas1, Athanasios Katsaounis1, Vyron Alexandrou1, Georgios Koimtzis1, Efstathios Pavlidis1, Anastasios Barmpas1, Theodora Tsiouda4, Chrysanthi Sardeli5, Zoi Aidoni6, Haidong Huang7, Qiang Li7, Wolfgang Hohenforst-Schmidt8, Isaak Kesisoglou1

1. 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
2. Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece.
3. Anesthisiology Department, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
4. Pulmonary Oncology Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece
5. Intensive Care Unit, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
6. Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
7. The Diagnostic and Therapeutic Center of Respiratory Diseases, Shanghai East Hospital, Tongji University, Shanghai, China.
8. Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, "Hof" Clinics, University of Erlangen, Hof, Germany.

Abstract

Introduction: Lung cancer is diagnosed at advanced stage due to lack of early disease symptoms. Currently we have several different biopsy techniques such as; radial endobronchial ultrasound, convex probe endobronchial ultrasound, electromagnetic navigation, ct guided biospy and transthoracic ultrasound biopsy. Novel therapies such as; immunotherapy is being used for non-small cell lung cancer in the everyday clinical practice as first and second line treatment. Programmed ligand-1 is essential in order to administer immunotherapy as first line treatment.

Patients and Methods: Two thousands and two patients were included in our study where programmed ligand 1 was evaluated with DAKO technique and BIOCARE®. Cell blocks were obtain with convex probe ebus-tbna 22G needle.

Results: The Deming regression between DAKO and BIOCARE clone revealed an amazingly strong linear relationship as the coefficient of determination indicated (R2=0.999) and the variance ratio close to 1 (0.978), proving that both techniques can equally well be substituted for each other. The regression coefficient equals to 1 and the intercept hardly differs from 0 (0.936). In practice, this relationship permits adopting the economically affordable BIOCARE clone for further medical considerations.

Conclusion: No statistical difference was observed between DAKO and BIOCARE®, therefore we propose that both techniques can be used in order to investigate the expression of programmed ligand 1 with safety. PD-L1 expression was higher in the central mass instead of the lymphnodes.

Keywords: NSCLC, PD-L1, convex probe EBUS, lymph nodes, lung cancer

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Sapalidis K, Zarogoulidis P, Petridis D, Kosmidis C, Fyntanidou B, Tsakiridis K, Maragouli E, Amaniti A, Giannakidis D, Koulouris C, Mantalobas S, Katsaounis A, Alexandrou V, Koimtzis G, Pavlidis E, Barmpas A, Tsiouda T, Sardeli C, Aidoni Z, Huang H, Li Q, Hohenforst-Schmidt W, Kesisoglou I. EBUS-TNBA 22G samples: Comparison of PD-L1 expression between DAKO and BIOCARE®. J Cancer 2019; 10(20):4739-4746. doi:10.7150/jca.35898. Available from http://www.jcancer.org/v10p4739.htm